Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Capecitabine + Pembrolizumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Capecitabine | Xeloda | R340|Ro 09-1978/000 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is a prodrug that is converted to 5-FU, ultimately inhibiting RNA and DNA synthesis and cell division (PMID: 28520372). Xeloda (capecitabine) is FDA-approved for use in patients with colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic cancer (FDA.gov). |
| Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, PMBL, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous SCC, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-positive NSCLC, esophageal SCC, cervical cancer, HNSCC, and TNBC, in combination with platnum-based chemo in NSCLC, with pemetrexed and platinum in pleural mesothelioma and non-sNSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in sNSCLC, with axitinib or lenvatinib in RCC, with lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, with platinum and fluoropyrimidine-based chemo for esophageal or gastroesophageal carcinoma, with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemo for CD274 (PD-L1)-positive, HER2-positive gastric or GEJ adenocarcinoma, with fluoropyrimidine- and platinum-containing chemo for HER2-negative gastric or GEJ adenocarcinoma, with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-positive cervical cancer, with gemcitabine and cisplatin for biliary tract cancer, with chemoradiation for cervical cancer, with carboplatin and paclitaxel for endometrial carcinoma, with paclitaxel with or without bevacizumab for epithelial ovarian, Fallopian tube, and peritonium cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04895358 | Phase III | Nab-paclitaxel Nab-paclitaxel + Pembrolizumab Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Capecitabine Pegylated liposomal doxorubicin Paclitaxel Pegylated liposomal doxorubicin + Pembrolizumab | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 11 |
| NCT06829199 | Phase II | Olaparib + Pembrolizumab Cyclophosphamide + Epirubicin + Pembrolizumab Cyclophosphamide + Doxorubicin + Pembrolizumab Cyclophosphamide + Epirubicin + MK-5890 + Pembrolizumab Cyclophosphamide + Doxorubicin + MK-5890 + Pembrolizumab Capecitabine + Pembrolizumab Carboplatin + MK-5890 + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) | Withdrawn | USA | 1 |
| NCT05629585 | Phase III | Datopotamab deruxtecan Capecitabine + Pembrolizumab Datopotamab deruxtecan + Durvalumab | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy | Active, not recruiting | USA | SWE | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | 5 |
| NCT04357587 | Phase I | Capecitabine + Pembrolizumab | Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer | Completed | USA | 0 |
| NCT06134375 | Phase Ib/II | Capecitabine Capecitabine + Tetrathiomolybdate Capecitabine + Pembrolizumab + Tetrathiomolybdate Capecitabine + Pembrolizumab | A Study of Tetrathiomolybdate (TM) Plus Capecitabine | Recruiting | USA | 0 |
| NCT03257163 | Phase II | Capecitabine + Pembrolizumab | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | Active, not recruiting | USA | 0 |
| NCT05973864 | Phase II | Pembrolizumab Capecitabine + Pembrolizumab | Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA) | Recruiting | FRA | 0 |
| NCT02734290 | Phase Ib/II | Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | Active, not recruiting | USA | 0 |
| NCT06393374 | Phase III | Pembrolizumab Pembrolizumab + SKB264 Capecitabine + Pembrolizumab | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT06831136 | Phase II | Capecitabine + Pembrolizumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pembrolizumab Cisplatin + Gemcitabine + Nab-paclitaxel + Pembrolizumab Gemcitabine + Nab-paclitaxel + Pembrolizumab Fluorouracil + Leucovorin + Liposomal irinotecan + Oxaliplatin + Pembrolizumab | Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma (PANCARDINAL-2) | Recruiting | USA | 0 |
| NCT05633654 | Phase III | Pembrolizumab + Sacituzumab govitecan-hziy Capecitabine + Pembrolizumab Pembrolizumab | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Recruiting | USA | IRL | GBR | FRA | ESP | DEU | AUS | 1 |
| NCT03044730 | Phase II | Capecitabine + Pembrolizumab | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | Unknown status | USA | 0 |
CKB BOOST